ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy", "AVO" or the "Company")
Rule 2.9 Announcement - Relevant Securities in Issue
In accordance with Rule 2.9 of the Takeover Code, AVO confirms that, as at the close of business on 2 May 2023, it had 4,975,125 senior secured fixed rate convertible loan notes ("Loan Notes") in issue, which have a maturity date of 11 January 2024 and are convertible into ordinary shares of 25p each in the company at a conversion price representing a 20% discount to the next equity fund raising undertaken by the Company. The Loan Notes pay an interest rate of 1.25% per month and includes a revenue sharing agreement with Harley Street Centre, as per the RNS dated 1 March 2023.
AVO also confirms that as at the close of business on 2 May 2023 its issued share capital consisted of 537,481,209 ordinary shares of 25 pence each. The International Securities Identification Number for the Company's ordinary shares is GB00BD6SX109.
Enquiries:
| Advanced Oncotherapy plc | |
| Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
| Nicolas Serandour, CEO | |
| | |
| WH Ireland Limited (Financial adviser) | Tel: +44 (0) 20 7220 1666 |
| Antonio Bossi / James Bavister | AVOPLC@whirelandcm.com |
| | |
| Allenby Capital Limited (Nomad and Joint Broker) | |
| Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales & Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
| | |
| SI Capital Ltd (Joint Broker) | |
| Nick Emerson | Tel: +44 (0) 1483 413 500 |
| Jon Levinson | Tel: +44 (0) 20 3871 4066 |
| | |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.